Last reviewed · How we verify
Cilostazol + Probucol group
This combination drug inhibits platelet aggregation and reduces cholesterol oxidation to improve blood flow and reduce cardiovascular events.
This combination drug inhibits platelet aggregation and reduces cholesterol oxidation to improve blood flow and reduce cardiovascular events. Used for Intermittent claudication and peripheral arterial disease, Atherosclerotic cardiovascular disease prevention.
At a glance
| Generic name | Cilostazol + Probucol group |
|---|---|
| Also known as | Pletaal and Changtai |
| Sponsor | Otsuka Beijing Research Institute |
| Drug class | Antiplatelet agent + Antioxidant lipid-lowering agent |
| Target | Phosphodiesterase-3 (cilostazol); LDL oxidation pathway (probucol) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Cilostazol is a phosphodiesterase-3 inhibitor that increases cAMP in platelets and vascular smooth muscle, promoting vasodilation and inhibiting platelet aggregation. Probucol is a lipophilic antioxidant that reduces LDL cholesterol oxidation and has antiatherosclerotic properties. Together, they work synergistically to improve peripheral circulation and reduce thrombotic risk.
Approved indications
- Intermittent claudication and peripheral arterial disease
- Atherosclerotic cardiovascular disease prevention
Common side effects
- Headache
- Palpitations
- Diarrhea
- Dizziness
Key clinical trials
- Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker (PHASE4)
- Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety (PHASE2)
- Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease (PHASE4)
- PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage (PHASE4)
- Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study) (PHASE4)
- Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cilostazol + Probucol group CI brief — competitive landscape report
- Cilostazol + Probucol group updates RSS · CI watch RSS
- Otsuka Beijing Research Institute portfolio CI